Zoetis Inc.

Zoetis Inc.

ZTSยทNYSE

$77.59

+1.6%
HealthcareDrug Manufacturers - General

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

At a Glance

Live Snapshot
Market Cap$32.53B
EPS6.0300
P/E Ratio12.87
Earnings Date08/04/2026
3Y+4.0%
5Y+14.0%
10Y+102.0%
3Y+15.0%
5Y+23.0%
10Y+97.0%
3Y-24.0%
5Y-12.0%
10Y+122.0%
zts

Zoetis Inc. Funding & Solvency Profile

ZTS ยท NYSE
Cash & Cash Equivalents2.31B
Net Receivables1.59B
Inventory2.43B
Other Current Assets436.00M
Total Current Assets7 B
Property, Plant & Equipment3.97B
Goodwill & Intangible Assets3.77B
Long-Term Investments0.00
Other Non-Current Assets328.00M
Total Non-Current Assets4 B
Total Assets
15.47B

Financial Health Analysis

Current Ratio

3.03x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

3.64x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

5 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

44% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Zoetis Inc. Balance Sheet

ZTS โ€ข NYSE

Zoetis Inc. Balance SheetDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010
ASSETS
CURRENT ASSETS
2.3B
2B
2B
3.6B
3.5B
3.6B
1.9B
1.6B
1.6B
727M
1.2B
882M
610M
317M
79M
63M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
99M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
2.3B
2B
2B
3.6B
3.5B
3.6B
1.9B
1.7B
1.6B
727M
1.2B
882M
610M
317M
79M
63M
1.6B
1.3B
1.3B
1.2B
1.1B
1B
1.1B
1B
998M
913M
937M
980M
1.1B
900M
871M
773M
1.6B
1.3B
1.3B
1.2B
1.1B
1B
1.1B
1B
998M
913M
937M
980M
1.1B
900M
871M
773M
2.4B
2.3B
2.6B
2.3B
1.9B
1.6B
1.4B
1.4B
1.4B
1.5B
1.5B
1.3B
1.3B
1.3B
1.1B
995M
436M
379M
436M
369M
392M
368M
320M
276M
228M
248M
272M
314M
316M
302M
298M
285M
6.8B
6B
6.3B
7.5B
6.9B
6.6B
4.7B
4.4B
4.2B
3.4B
3.8B
3.5B
3.4B
2.9B
2.3B
2.1B
NON-CURRENT ASSETS
4B
3.6B
3.4B
3B
2.6B
2.4B
2.1B
1.7B
1.4B
1.4B
1.3B
1.3B
1.3B
1.2B
1.2B
1.1B
2.8B
2.7B
2.8B
2.7B
2.7B
2.7B
2.6B
2.5B
1.5B
1.5B
1.5B
976M
982M
985M
989M
934M
998M
1.1B
1.3B
1.4B
1.5B
1.7B
1.9B
2B
1.3B
1.2B
1.2B
727M
803M
868M
928M
924M
3.8B
3.9B
4.1B
4.1B
4.2B
4.4B
4.5B
4.6B
2.8B
2.7B
2.6B
1.7B
1.8B
1.9B
1.9B
1.9B
0.0
30M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
637M
540M
206M
173M
100M
94M
88M
61M
80M
96M
82M
54M
63M
216M
143M
70M
328M
220M
206M
147M
111M
106M
98M
94M
75M
73M
49M
48M
58M
88M
97M
92M
8.7B
8.3B
7.9B
7.4B
7B
7B
6.8B
6.4B
4.4B
4.3B
4.1B
3.1B
3.2B
3.4B
3.4B
3.2B
15.5B
14.2B
14.3B
14.9B
13.9B
13.6B
11.5B
10.8B
8.6B
7.6B
7.9B
6.6B
6.6B
6.3B
5.7B
5.3B
LIABILITIES
CURRENT LIABILITIES
866M
750M
719M
736M
628M
622M
432M
427M
382M
388M
403M
358M
582M
349M
232M
230M
487M
433M
411M
405M
436M
457M
301M
313M
261M
265M
293M
290M
506M
319M
214M
206M
379M
317M
308M
331M
192M
165M
131M
114M
121M
123M
110M
68M
76M
30M
18M
24M
410M
746M
683M
682M
710M
556M
543M
487M
432M
464M
676M
475M
570M
0.0
0.0
0.0
53M
1.4B
3M
1.4B
0.0
604M
500M
9M
0.0
0.0
405M
7M
15M
73M
0.0
38M
147M
93M
110M
157M
38M
46M
36M
35M
60M
71M
63M
26M
40M
30M
18M
24M
11M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
895M
566M
484M
397M
459M
388M
331M
300M
280M
265M
297M
246M
248M
701M
611M
540M
2.2B
3.4B
1.9B
3.2B
1.8B
2.2B
1.8B
1.2B
1.1B
1.1B
1.8B
1.1B
1.4B
1.1B
843M
808M
NON-CURRENT LIABILITIES
9.2B
5.2B
6.6B
6.6B
6.6B
6.6B
5.9B
6.4B
5B
4.5B
4.5B
3.6B
3.6B
509M
575M
673M
17M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
139M
167M
146M
142M
320M
378M
434M
474M
380M
244M
264M
277M
322M
323M
311M
218M
305M
494M
508M
475M
496M
530M
486M
452M
373M
321M
314M
264M
217M
266M
246M
241M
9.9B
6.1B
7.4B
7.4B
7.6B
7.7B
7B
7.4B
5.7B
5B
5B
4.2B
4.2B
1.1B
1.1B
1.1B
202M
174M
188M
186M
151M
163M
164M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
12.1B
9.5B
9.3B
10.5B
9.4B
9.8B
8.8B
8.6B
6.8B
6.2B
6.8B
5.3B
5.6B
2.2B
2B
1.9B
SHAREHOLDERS' EQUITY
-10.7B
-7.4B
-5.6B
-4.5B
-3B
-2.2B
-2B
-1.5B
-852M
-421M
-203M
0.0
0.0
0.0
0.0
0.0
5M
5M
5M
5M
5M
5M
5M
5M
5M
5M
5M
5M
5M
0.0
0.0
0.0
1.1B
1.2B
1.1B
1.1B
1.1B
1.1B
1B
1B
1B
1B
1B
958M
878M
0.0
0.0
0.0
13.7B
12B
10.3B
8.7B
7.2B
5.7B
4.4B
3.3B
2.1B
1.5B
876M
709M
276M
0.0
0.0
0.0
-834M
-940M
-839M
-817M
-764M
-730M
-726M
-629M
-505M
-598M
-622M
-361M
-219M
-157M
-65M
-74M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
4.2B
3.8B
3.4B
3.3B
4.8B
5B
4.4B
4.5B
3.8B
2.7B
2.2B
1.8B
1.5B
1.1B
1.3B
940M
4B
3.7B
3.3B
3.3B
4.8B
5B
4.4B
4.5B
3.8B
2.7B
2.2B
1.8B
1.5B
1.1B
1.3B
962M
4B
3.7B
3.3B
0.0
0.0
-6M
-2M
1M
4M
0.0
0.0
16M
12M
23M
26M
22M
15M
16M
0.0
SUMMARY
15.5B
14.2B
14.3B
14.9B
13.9B
13.6B
11.5B
10.8B
8.6B
7.6B
7.9B
6.6B
6.6B
6.3B
5.7B
5.3B
0.0
30M
0.0
0.0
0.0
0.0
0.0
99M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
9.5B
6.7B
6.8B
8.1B
6.7B
7.4B
6.6B
6.5B
5B
4.5B
4.9B
3.6B
3.7B
582M
575M
711M
7.2B
4.8B
4.7B
4.5B
3.3B
3.8B
4.7B
4.9B
3.4B
3.7B
3.7B
2.7B
3B
265M
496M
648M
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214
440,693,214

SEC Filings

ZTS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 22, 2026
May 20, 2026
2026
8-K

8-K 2026

N/A

May 20, 2026
May 20, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 08, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

February 12, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 12, 2026
February 12, 2026
2026
8-K

8-K 2026

N/A

February 05, 2026
February 05, 2026
2026
8-K

8-K 2025

N/A

December 18, 2025
December 15, 2025
2025
8-K

8-K 2025

N/A

December 11, 2025
December 11, 2025
2025
Showing 1 to 10 of 258 filings